| JARDIN, Fabrice |
MorningLyte, NCT06284122: Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 |
|
|
| Recruiting | 3 | 790 | Europe | Mosunetuzumab, Lenalidomide, Rituximab, Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristin, Prednisone, Bendamustin | The Lymphoma Academic Research Organisation, Lymphoma Study Association, Swiss Group for Clinical Cancer Research, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Follicular Lymphoma | 11/28 | 04/34 | | |
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Active, not recruiting | 3 | 440 | Europe, Canada, Japan, US, RoW | Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin | ADC Therapeutics S.A., ADC Therapeutics SA | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 06/25 | 06/28 | | |
|
|
|
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
AVAJAK, NCT05198960: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms |
|
|
| Recruiting | 3 | 1308 | Europe | Direct Oral Anticoagulants, Low-dose aspirin | University Hospital, Brest | Polycythemia Vera, Essential Thrombocythemia, Prefibrotic/Early Primary Myelofibrosis, JAK2 V617F, High-risk Patients | 07/27 | 07/27 | | |
MARSUN, NCT06006117: Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma |
|
|
| Recruiting | 3 | 260 | Europe | Mosunetuzumab + Lenalidomide, Arm 1, - Rituximab + Lenalidomide (28-days cycles, Arm 2, - Rituximab + Bendamustine (28-days cycles), Arm 3, - Rituximab + CHOP (21-days cycles), Arm 4 | The Lymphoma Academic Research Organisation | Marginal Zone Lymphoma | 09/27 | 09/32 | | |
NCT06271057: Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse |
|
|
| Recruiting | 2 | 65 | Europe | golcadomide, BMS-986369, CC-99282 | The Lymphoma Academic Research Organisation, Lymphoma Study Association | Diffuse Large B-cell Lymphoma Refractory, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory High Grade B-Cell Lymphoma | 01/26 | 10/27 | | |
VERLen, NCT04974216: Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older |
|
|
| Active, not recruiting | 2 | 71 | Europe | Tafasitamab, MOR208, Lenalidomide, Rituximab | The Lymphoma Academic Research Organisation | DLBCL | 07/24 | 12/26 | | |
Relyage, NCT04113226: Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 2 | 114 | Europe | Rituximab, Lenalidomide 20 MG, Comprehensive Geriatric Assessment (CGA), Activities of daily living (ADL) scale | Centre Hospitalier Universitaire, Amiens, cimiez hospital Nice, Institut Bergonié, groupe hospitalier public sud de l'oise, Henri Mondor University Hospital, Centre Henri Becquerel, Hôpital Charles Foix, Saint-Louis Hospital, Paris, France | Chemotherapy, Diffuse Large B-Cell Lymphoma (DLBCL), Nos, Elderly | 12/24 | 12/24 | | |
GLOASIS, NCT06558604: A Phase II Study Evaluating Glofitamab in Combination With Venetoclax Plus Zanubrutinib or Venetoclax Alone in Subjects With Untreated or Relapsed/Refractory High-risk Mantle-cell Lymphoma |
|
|
| Recruiting | 2 | 100 | Europe | Obinutuzumab, Glofitamab, Venetoclax Oral Product, Zanubrutinib Oral Capsule | The Lymphoma Academic Research Organisation, BeiGene, Hoffmann-La Roche | Lymphoma, Mantle-Cell | 05/28 | 03/32 | | |
| Recruiting | 1/2 | 118 | Europe, RoW | Lenalidomide, Revlimid, Ibrutinib, Imbruvica | Institut Curie, National Cancer Institute, France | Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Primary | 02/25 | 02/35 | | |
| Terminated | N/A | 139 | Europe | blood sample analyses | Intergroupe Francophone du Myelome | Multiple Myeloma, Covid19 | 12/22 | 12/22 | | |
| Recruiting | N/A | 100 | Europe | Physical exercises, Optional physical exercises | Centre Hospitalier Universitaire, Amiens, University Hospital, Rouen, University Hospital, Caen | Physical Activity, Multiple Myeloma, Quality of Life | 05/23 | 12/23 | | |
| Not yet recruiting | N/A | 12 | Europe | Measure of the circulating tumor DNA | Centre Henri Becquerel | Diffuse Large B Cell Lymphoma | 11/24 | 05/25 | | |
DECLAM, NCT03450512: Incidence of Neutropenic Enterocolitis Study in Acute Myeloid Leukemia Patients During Intensive Therapy |
|
|
| Recruiting | N/A | 170 | Europe | prospective study on digestive affections in an homogeneous cohort of hematological patients | Centre Hospitalier Universitaire, Amiens | Acute Myeloid Leukemia | 11/24 | 11/24 | | |
| Recruiting | N/A | 100 | Europe | fundoscopic picture, blood sample, bone marrow sample | Centre Hospitalier Universitaire, Amiens, Centre Hospitalier Saint Vincent, Centre Henri Becquerel, University Hospital, Caen, University Hospital, Lille, Centre Hospitalier de Lens | Hyperviscosity Syndrome, Waldenstrom Macroglobulinemia | 05/24 | 08/24 | | |
SLP-rares, NCT04893564: Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia |
|
|
| Withdrawn | N/A | 90 | Europe | bone marrow sample, blood sample | Centre Hospitalier Universitaire, Amiens, Centre Henri Becquerel, University Hospital, Caen, University Hospital, Lille, Centre Hospitalier de Lens | Waldenstrom's Disease, Waldenstrom Macroglobulinemia | 05/24 | 05/24 | | |
REMODALLO, NCT05161026: Impact of Allo-HSCT on Bone Remodeling: Evolution of Bone Mineral Density and Architecture Measured by Bone Densitometry |
|
|
| Not yet recruiting | N/A | 120 | Europe | Bone osteodensitometry | University Hospital, Caen | Myeloid Leukemia, Acute | 12/26 | 12/27 | | |
| Recruiting | N/A | 6000 | Europe | Real-life epidemiological platform of lymphoma in France | Hospices Civils de Lyon, The Lymphoma Academic Research Organisation | Diffuse Large B Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), T-cell Lymphoma (T-NHL), Hodgkin's Lymphoma (HL), Burkitt Lymphoma (BL)) | 11/27 | 11/27 | | |
NCT04220970: Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry |
|
|
| Recruiting | N/A | 150 | Europe | BIA-ALCL | The Lymphoma Academic Research Organisation | Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL) | 06/32 | 06/32 | | |
| Recruiting | N/A | 5000 | Europe | | The Lymphoma Academic Research Organisation, Gilead Sciences, Novartis, Bristol-Myers Squibb | Hematopathology Eligible or CAR-t Cell Treatment | 12/38 | 12/38 | | |
| Tempescul, Adrian |
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Active, not recruiting | 3 | 440 | Europe, Canada, Japan, US, RoW | Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin | ADC Therapeutics S.A., ADC Therapeutics SA | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 06/25 | 06/28 | | |
|
|
|
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
OASIS-II, NCT04802590: Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma |
|
|
| Recruiting | 2 | 194 | Europe | Ibrutinib 560 mg, Venetoclax 10 MG Oral Tablet [Venclexta], Venetoclax 50 MG Oral Tablet [Venclexta], Venetoclax 100 MG Oral Tablet [Venclexta] | The Lymphoma Academic Research Organisation, Institute of Cancer Research, United Kingdom | Mantle Cell Lymphoma | 03/26 | 09/31 | | |
NCT04220970: Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry |
|
|
| Recruiting | N/A | 150 | Europe | BIA-ALCL | The Lymphoma Academic Research Organisation | Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL) | 06/32 | 06/32 | | |
| Recruiting | N/A | 5000 | Europe | | The Lymphoma Academic Research Organisation, Gilead Sciences, Novartis, Bristol-Myers Squibb | Hematopathology Eligible or CAR-t Cell Treatment | 12/38 | 12/38 | | |
| Gastinne, Thomas |
MorningLyte, NCT06284122: Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 |
|
|
| Recruiting | 3 | 790 | Europe | Mosunetuzumab, Lenalidomide, Rituximab, Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristin, Prednisone, Bendamustin | The Lymphoma Academic Research Organisation, Lymphoma Study Association, Swiss Group for Clinical Cancer Research, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Follicular Lymphoma | 11/28 | 04/34 | | |
| Recruiting | 3 | 225 | Europe, Canada, Japan, US, RoW | Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B) | F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi | Invasive Aspergillosis | 09/25 | 11/26 | | |
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
| Active, not recruiting | 3 | 240 | Europe, Canada, US, RoW | Brentuximab vedotin, Rituximab, Lenalidomide, Placebo | Seagen Inc. | Diffuse Large B-cell Lymphoma | 05/25 | 04/27 | | |
|
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
| Active, not recruiting | 2 | 168 | Europe, RoW | MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab | Miltenyi Biomedicine GmbH, ICON plc | Diffuse Large B-cell Lymphoma | 12/24 | 07/29 | | |
| Recruiting | 2 | 56 | Europe | Lacutamab, Gemcitabine, Oxaliplatine | The Lymphoma Academic Research Organisation, Innate Pharma | Peripheral T Cell Lymphoma, Relapse/Recurrence | 01/25 | 01/27 | | |
|
| Recruiting | 2 | 180 | Europe, Japan, US, RoW | Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid® | Genmab, AbbVie | Diffuse Large B-Cell Lymphoma | 01/26 | 03/27 | | |
| Recruiting | 1/2 | 118 | Europe, RoW | Lenalidomide, Revlimid, Ibrutinib, Imbruvica | Institut Curie, National Cancer Institute, France | Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Primary | 02/25 | 02/35 | | |
| Recruiting | 1/2 | 210 | Europe, US, RoW | CPI-0209 | Constellation Pharmaceuticals | Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma | 12/25 | 03/26 | | |
| Recruiting | N/A | 6000 | Europe | Real-life epidemiological platform of lymphoma in France | Hospices Civils de Lyon, The Lymphoma Academic Research Organisation | Diffuse Large B Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), T-cell Lymphoma (T-NHL), Hodgkin's Lymphoma (HL), Burkitt Lymphoma (BL)) | 11/27 | 11/27 | | |
| Recruiting | N/A | 5000 | Europe | | The Lymphoma Academic Research Organisation, Gilead Sciences, Novartis, Bristol-Myers Squibb | Hematopathology Eligible or CAR-t Cell Treatment | 12/38 | 12/38 | | |
| Jiang, Bo |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
NCT05181137 / 2021-001940-86: A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 3 | 368 | Europe, US, RoW | SHR0302, Placebo | Reistone Biopharma Company Limited, Reistone Biopharma Company Limited | Ulcerative Colitis | 10/24 | 03/25 | | |
NCT06206174: TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies |
|
|
| Recruiting | 1/2 | 30 | RoW | TGRX-814, TGRX-814 monotherapy | Shenzhen TargetRx, Inc., Institute of Hematology & Blood Diseases Hospital, China | Hematologic Malignancy, Non Hodgkin Lymphoma, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult, Myelodysplastic Syndromes | 02/25 | 02/29 | | |
NCT04322006: A Phase I/II Study of TJ004309 for Advanced Solid Tumor |
|
|
| Active, not recruiting | 1/2 | 376 | RoW | TJ004309, Toripalimab | TJ Biopharma Co., Ltd. | Advanced Solid Tumor | 12/24 | 12/24 | | |
NCT05380427: A Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of CU-40101 Liniment in Single and Multiple Doses in Adult Male Androgenic Alopecia Subjects |
|
|
| Completed | 1 | 80 | RoW | CU-40101 | Cutia Therapeutics（Wuxi）Co.,Ltd | AGA | 11/23 | 02/24 | | |
HRS-7249-101, NCT06541457: A Study on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7249 Injection in Healthy Subjects |
|
|
| Recruiting | 1 | 48 | RoW | HRS-7249 injection, Placebo | Fujian Shengdi Pharmaceutical Co., Ltd. | Hyperlipidemia | 05/25 | 05/25 | | |
NCT04872491: A Study of Vedolizumab in Adults in Real-World Practice |
|
|
| Completed | N/A | 500 | RoW | | Takeda | Colitis, Ulcerative, Crohn Disease | 07/24 | 07/24 | | |
| Yao, Ke |
NCT06196840: Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS) |
|
|
| Recruiting | 2 | 50 | RoW | LX102 subretinal injection, Aflibercept intravitreal injection | Innostellar Biotherapeutics Co.,Ltd | Neovascular Age-Related Macular Degeneration | 05/25 | 05/29 | | |
NCT06183814: A Study of EXG102-031 in Participants With wAMD |
|
|
| Recruiting | 1/2 | 42 | RoW | EXG102-031 | Hangzhou Jiayin Biotech Ltd | Neovascular Age-related Macular Degeneration | 12/25 | 12/25 | | |
NCT06198413: LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD) |
|
|
| Recruiting | 1 | 12 | RoW | LX102 subretinal injection | Innostellar Biotherapeutics Co.,Ltd | Neovascular Age-Related Macular Degeneration | 01/25 | 01/29 | | |
NCT05268718: Au-Ag-Cu2O NG With PTT Anti Drug-resistant Microbial Keratitis |
|
|
| Recruiting | 1 | 20 | RoW | Hollow gold and silver alloy cuprous oxide shell nano-shell hydrogel, Au-Ag-Cu2O nano-gel, Voriconazole eye drops, VRC, Normal saline, NS | Second Affiliated Hospital, School of Medicine, Zhejiang University | Keratitis, Ulcerative, Antibiotic Resistance, Microbial, Photothermal Therapy | 12/23 | 07/24 | | |
NCT06215807: Femtosecond Laser Arcuate Keratotomy Versus Toric Intraocular Lens Implantation in Cataract Surgery |
|
|
| Recruiting | N/A | 200 | RoW | Femtosecond laser arcuate keratotomy, Toric intraocular lens implantation | Second Affiliated Hospital, School of Medicine, Zhejiang University | Cataract, Astigmatism | 01/25 | 01/26 | | |
| Yuan, Ying |
NCT05362617: mFOLXOX6 Versus FOLFIRI for Colorectal Patients Recurrence After Oxaplatin Based Adjuvant Chemotherapy |
|
|
| Recruiting | 3 | 328 | RoW | FOLFIRI | Second Affiliated Hospital, School of Medicine, Zhejiang University | Metastatic Colorectal Cancer | 12/22 | 12/23 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
NCT05171660: Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer |
|
|
| Recruiting | 3 | 436 | RoW | Sintilimab Injection, bevacizumab, Oxaliplatin, Capecitabine, Control Test, XELOX + Bevacizumab | Second Affiliated Hospital, School of Medicine, Zhejiang University | Colorectal Cancer Stage IV | 12/24 | 06/25 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
| Recruiting | 3 | 306 | RoW | Chidamide, Cladribine, Gemcitabine, Busulfan, Carmustine, Etoposide, Cytarabine, Melphalan, Autologous hematopoietic stem cell transplant | Sichuan University | Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell | 12/25 | 12/25 | | |
NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer |
|
|
| Active, not recruiting | 3 | 878 | RoW | JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy | Shanghai Junshi Bioscience Co., Ltd. | Gastric or Esophagogastric Junction Adenocarcinoma | 06/26 | 07/28 | | |
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer |
|
|
| Recruiting | 3 | 711 | Europe, Canada, Japan, US, RoW | Dostarlimab, CAPEOX, FOLFOX | GlaxoSmithKline | Colonic Neoplasms, Neoplasms, Colon | 12/28 | 12/30 | | |
NCT05409417: Exploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status |
|
|
| Recruiting | 2/3 | 40 | RoW | Experimental drug, Tilelizumab combined with chemotherapy | Second Affiliated Hospital, School of Medicine, Zhejiang University | Colorectal Cancer, Liver Metastases | 02/24 | 09/24 | | |
BEVTOR, NCT04527068: QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 50 | RoW | Bevacizumab, QL1101, Tripleitriumab, JS001 | Second Affiliated Hospital, School of Medicine, Zhejiang University, Qilu Pharmaceutical Co., Ltd., Shanghai Junshi Bioscience Co., Ltd. | Refractory Metastatic Colorectal Cancer, pMMR, MSS | 09/21 | 02/22 | | |
BBCAPX-II, NCT04194359: Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 25 | RoW | Sintilimab (IBI308)+bevacizumab+oxaliplatin+capecitabine | Second Affiliated Hospital, School of Medicine, Zhejiang University | Metastatic Colorectal Cancer, RAS Mutation, Microsatellite Stable | 11/22 | 12/23 | | |
| Recruiting | 2 | 50 | RoW | Raltitrexed combined with oxaplatin, Sai Wei Jian | Second Affiliated Hospital, School of Medicine, Zhejiang University | Cholangioadenoma | 12/22 | 12/23 | | |
NCT04733963: Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 112 | RoW | Fruquintinib Plus Capecitabine, Bevacizumab Plus Capecitabine | Second Affiliated Hospital, School of Medicine, Zhejiang University | Colorectal Cancer | 01/23 | 02/23 | | |
NCT05160896: SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 90 | RoW | Raltitrexed, Sai Wei Jian, Irinotecan, CPT-11, Bevacizumab, Avastin, Cetuximab, ERBITUX | Second Affiliated Hospital, School of Medicine, Zhejiang University | Advanced Metastatic Colorectal Cancer | 06/23 | 06/23 | | |
NCT06134765: Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer |
|
|
| Not yet recruiting | 2 | 89 | RoW | Bemalenograstim alfa, F-627 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Colorectal Cancer, Pancreatic Cancer | 10/24 | 03/25 | | |
NCT05785325: RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer |
|
|
| Recruiting | 2 | 30 | RoW | RC48-ADC plus Bevacizumab | Second Affiliated Hospital, School of Medicine, Zhejiang University | Colorectal Cancer | 12/23 | 12/24 | | |
NCT05894837: Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver Metastases |
|
|
| Not yet recruiting | 2 | 30 | RoW | Serplulimab+Regorafenib, Hepatic Artery Bicarbonate Infusion | Second Affiliated Hospital, School of Medicine, Zhejiang University | Colorectal Cancer, Liver Metastases | 06/24 | 06/25 | | |
NCT05555901: The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 116 | RoW | Fruquintinib+ chemotherapy, Bevacizumab+ chemotherapy | Fudan University | Metastatic Colorectal Cancer | 09/25 | 09/25 | | |
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 320 | RoW | TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab | Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb | Advanced Cancer | 02/25 | 05/25 | | |
NCT06214143: A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 68 | RoW | T3011 high dose, T3011 middle dose, T3011 low dose | Shanghai Pharmaceuticals Holding Co., Ltd | Advanced Solid Tumors | 12/25 | 05/26 | | |
NCT05260385: To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors |
|
|
| Recruiting | 1/2 | 133 | RoW | KC1036 | Beijing Konruns Pharmaceutical Co., Ltd. | Digestive System Tumors | 10/25 | 12/25 | | |
NCT05338957: A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. |
|
|
| Recruiting | 1/2 | 30 | RoW | MRG002+HX008 | Shanghai Miracogen Inc. | Advanced Malignant Solid Tumors | 06/24 | 12/24 | | |
NCT06500676: A Study of GFH375 in Patients with Advanced Solid Tumors with KRAS G12D Mutations |
|
|
| Recruiting | 1/2 | 290 | RoW | GFH375 | Genfleet Therapeutics (Shanghai) Inc. | KRAS G12D Mutations, Advanced Solid Tumors | 07/28 | 12/28 | | |
| Recruiting | 1 | 60 | RoW | SG1906 | Hangzhou Sumgen Biotech Co., Ltd. | Locally Advanced Unresectable or Metastatic Solid Tumors | 02/25 | 08/25 | | |
NCT05501912: A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors |
|
|
| Terminated | 1 | 20 | RoW | ABM-1310 | ABM Therapeutics Shanghai Company Limited | Advanced Solid Tumor, BRAF V600 Mutation | 06/24 | 06/24 | | |
NCT04819516: Study of the Safety and Effectiveness of HIFU Combined With REGOTORI for Metastatic Colorectal Cancer |
|
|
| Recruiting | 1 | 10 | RoW | high-intensity focused ultrasound therapy, Toripalimab, Regorafenib | Second Affiliated Hospital, School of Medicine, Zhejiang University | Colorectal Cancer | 12/25 | 12/25 | | |
NCT06043466: A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | CEA-targeted CAR-T cells | Chongqing Precision Biotech Co., Ltd, Zhejiang University | Colorectal Cancer, Esophagus Cancer, Gastric Cancer, Pancreas Cancer, Non-small Cell Lung Cancer, Breast Cancer, Bile Duct Cancer | 12/26 | 12/27 | | |
INSPPIRE 2, NCT06651580: Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, Study |
|
|
| Recruiting | N/A | 1600 | Canada, US, RoW | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration | M.D. Anderson Cancer Center, National Cancer Institute (NCI) | Chronic Pancreatitis, Exocrine Pancreas Carcinoma, Recurrent Acute Pancreatitis | 02/27 | 02/27 | | |
NCT03958435: Real-world Retrospective Data Analysis of Adjuvant Therapy for Patients With Stage II-III Colon Cancer After Radical Surgery |
|
|
| Recruiting | N/A | 20000 | RoW | | Second Affiliated Hospital, School of Medicine, Zhejiang University | Stage II Colon Cancer, Stage III Colon Cancer, Adjuvant Therapy | 10/22 | 12/23 | | |
NCT04961125: Multicenter Study on the Pathogenic Germline Gene Variants of Colorectal Polyposis in China |
|
|
| Recruiting | N/A | 200 | RoW | germline variants | Second Affiliated Hospital, School of Medicine, Zhejiang University | Colorectal Polyposis | 12/22 | 12/24 | | |
NCT06101030: Comparing Use of Incentive Spirometry with and Without Reminder |
|
|
| Recruiting | N/A | 500 | US | Signal On | Tidal Medical Technologies | Post Operative | 03/25 | 07/25 | | |
SUMMIT, NCT03433274: Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation |
|
|
| Recruiting | N/A | 958 | Canada, US | Tendyne Mitral Valve System, MitraClip System | Abbott Medical Devices | Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Insufficiency, Cardiovascular Diseases, Valve Disease, Heart, Heart Valve Diseases, Functional Mitral Regurgitation, Degenerative Mitral Valve Disease | 05/24 | 06/28 | | |
ICE-AFIB, NCT03732794: AtriCure CryoICE Lesions for Persistent and Long-standing Persistent Atrial Fibrillation Treatment |
|
|
| Active, not recruiting | N/A | 150 | US | AtriCure CryoICE & AtriClip LAA Exclusion | AtriCure, Inc. | Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Longstanding Persistent Atrial Fibrillation | 06/24 | 06/26 | | |
NCT03460769: Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT) |
|
|
| Recruiting | N/A | 600 | US | Data Management and Monitoring | M.D. Anderson Cancer Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Pancreatic Cancer, Chronic Pancreatitis, Diabetes Mellitus Type 3c | 06/25 | 06/25 | | |
| Drenou, Bernard |
MorningLyte, NCT06284122: Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 |
|
|
| Recruiting | 3 | 790 | Europe | Mosunetuzumab, Lenalidomide, Rituximab, Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristin, Prednisone, Bendamustin | The Lymphoma Academic Research Organisation, Lymphoma Study Association, Swiss Group for Clinical Cancer Research, Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Follicular Lymphoma | 11/28 | 04/34 | | |
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
| Active, not recruiting | 2 | 82 | Europe, US, RoW | brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone | Seagen Inc. | Peripheral T-cell Lymphoma | 05/24 | 12/25 | | |
STAIR, NCT04963946: STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia |
|
|
| Recruiting | 2 | 160 | Europe | Stop ACA, ACA Continuation | French Innovative Leukemia Organisation | Untreated Chronic Lymphocytic Leukemia | 01/26 | 08/28 | | |
| Active, not recruiting | 2 | 141 | Europe | Valemetostat tosylate, DS-3201b | The Lymphoma Academic Research Organisation, Daiichi Sankyo | Lymphoma, B-Cell | 10/24 | 10/24 | | |
NCT01976182: Prospective, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia |
|
|
| Completed | 2 | 166 | Europe | Methotrexate, Cyclophosphamide | Rennes University Hospital | Large Granular Lymphocytes Leukemia | 02/24 | 10/24 | | |
NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
|
|
| Recruiting | 2 | 249 | Europe, Canada, US, RoW | Pirtobrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 06/28 | 12/28 | | |
COVID19_LLC-MW, NCT04391946: Observatory of Patients With Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenstrom Disease Infected With COVID-19 |
|
|
| Completed | N/A | 162 | Europe | Data registry | French Innovative Leukemia Organisation, Institut de cancérologie Strasbourg Europe | Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma or Waldenstrom Disease | 03/22 | 03/23 | | |
THEMIS, NCT05350826: Evaluation of the Ambulatory Medical Assistance Nurse Program in Chronic Lymphocytic Leukemia |
|
|
| Recruiting | N/A | 450 | Europe | Ambulatory medical assistance | University Hospital, Toulouse | Chronic Lymphoid Leukemia | 07/25 | 07/25 | | |
FOLLOW, NCT05590702: French Observational Study of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in Real-World Settings |
|
|
| Recruiting | N/A | 1000 | Europe | First line therapy | French Innovative Leukemia Organisation, AbbVie, AstraZeneca, BeiGene, Janssen-Cilag Ltd. | CLL/SLL | 11/25 | 12/32 | | |
Quali-SAT, NCT04779593: Impact of Transferrin Saturation Guided Maintenance Treatment on Quality of Life in HFE Haemochromatosis |
|
|
| Recruiting | N/A | 240 | Europe | Clinical examination, SF36 questionnaire, AIMS2_SF questionnaire, WOMAC questionnaire, EQ-5D-5L questionnaire, Blood Sample Complete blood count, Blood Sample Iron panel, Blood Sample Fasting Glucose, Blood sample lipid panel, Blood sample liver panel, Blood sample C reactive protein, Bloodletting - control group, BioBank, Medico-economical, Bloodletting - experimental group | Rennes University Hospital | Haemochromatosis | 01/27 | 01/27 | | |
| Recruiting | N/A | 6000 | Europe | Real-life epidemiological platform of lymphoma in France | Hospices Civils de Lyon, The Lymphoma Academic Research Organisation | Diffuse Large B Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), T-cell Lymphoma (T-NHL), Hodgkin's Lymphoma (HL), Burkitt Lymphoma (BL)) | 11/27 | 11/27 | | |
| Qian, Wenbin |
NCT06134284: Clinical Study of OR for Second-line Treatment of Refractory MZL |
|
|
| Recruiting | 4 | 39 | RoW | Orelabrutinib combined with rituximab | Lixia Sheng | OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma | 12/26 | 12/29 | | |
NCT04910594: Clinical Study the Efficacy and Safety of Rh-EPO in the Treatment of Anemia in Lymphoma |
|
|
| Recruiting | 3 | 130 | RoW | recombinant human erythropoietin, EPO | Second Affiliated Hospital, School of Medicine, Zhejiang University, First People's Hospital of Hangzhou, Zhejiang Provincial Tongde Hospital, The First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Cancer Hospital, Wenzhou Central Hospital, First Affiliated Hospital of Wenzhou Medical University, Ningbo Medical Center Lihuili Hospital, First Affiliated Hospital of Jiaxing University, Taizhou Hospital of Zhejiang Province, Second Affiliated Hospital of Wenzhou Medical University | Lymphoma, Anemia | 02/23 | 04/23 | | |
| Recruiting | 3 | 240 | RoW | Equecabtagene Autoleucel Injection, FUCASO, Daratumumab, Pomalidomide, Bortezomib, Dexamethasone | Nanjing IASO Biotechnology Co., Ltd. | Multiple Myeloma | 08/27 | 12/30 | | |
NCT06363994: A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL |
|
|
| Recruiting | 3 | 476 | RoW | Orelabrutinib, Bendamustine Injection, Rituximab, Orelabrutinib Placebo | InnoCare Pharma Inc. | Mantle Cell Lymphoma | 06/31 | 06/32 | | |
NCT06508983: A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients |
|
|
| Recruiting | 3 | 360 | RoW | SG301 Injection, SG301 placebo, pomalidomide, dexamethasone | Hangzhou Sumgen Biotech Co., Ltd. | Relapsed/Refractory Multiple Myeloma | 03/27 | 03/28 | | |
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
